Cytek Biosciences
CTKB
103 hedge funds and large institutions have $654M invested in Cytek Biosciences in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 24 reducing their positions, and 10 closing their positions.
2,925% more call options, than puts
Call options by funds: $1.97M | Put options by funds: $65K
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
75% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 24
17% more funds holding
Funds holding: 88 → 103 (+15)
2.15% more ownership
Funds ownership: 45.35% → 47.5% (+2.2%)
27% less capital invested
Capital invested by funds: $899M → $654M (-$245M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$14.1M |
| 2 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$9.43M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$6.41M |
| 4 |
BlackRock
New York
|
+$6.05M |
| 5 |
Goldman Sachs
New York
|
+$3.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$10.8M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$3.71M |
| 3 |
Millennium Management
New York
|
-$3.68M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.3M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$1.43M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Group One Trading
Chicago,
Illinois
| $623 | +$820 | +61 | New |
|
|
BC
102
Brookfield Corp
Toronto,
Ontario, Canada
| – | -$987K | -67,084 | Closed |
|
|
AR
103
Advisory Research
Chicago,
Illinois
| – | -$614K | -41,750 | Closed |
|
104
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$545K | -40,559 | Closed |
|
105
Wellington Management Group
Boston,
Massachusetts
| – | -$471K | -31,981 | Closed |
|
106
AQR Capital Management
Greenwich,
Connecticut
| – | -$459K | -31,163 | Closed |
|
107
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$185K | -12,568 | Closed |
|
|
OQS
108
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
| – | -$166K | -11,253 | Closed |
|
|
QT
109
Quantamental Technologies
White Plains,
New York
| – | -$148K | -10,040 | Closed |
|
110
Ensign Peak Advisors
Salt Lake City,
Utah
| – | -$106K | -7,210 | Closed |
|
|
CA
111
Crewe Advisors
Salt Lake City,
Utah
| – | -$1K | -77 | Closed |
|
|
C
112
Covestor
London,
United Kingdom
| – | -$13 | -1 | -7% |
|
113
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$161 | +12 | New |
|
CTKB Hedge Fund Activity: Q4 2022 in Review
103 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q4 2022, worth a combined $654M — down 27% from $899M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CTKB positions and 10 closed out — a net gain of 15 holders — while 42 added to existing stakes and 24 trimmed.
The largest buyer was Macquarie Group, opening a new position worth an estimated $14.1M. The largest seller was Blue Water Life Science Advisors, cutting an estimated $10.8M.
- 103 institutional investors held Cytek Biosciences (CTKB) as of Q4 2022, up from 88 in Q3 2022.
- Funds reported $654M of Cytek Biosciences stock for Q4 2022, down 27% quarter-over-quarter.
- 25 funds opened new Cytek Biosciences positions in Q4 2022 and 10 closed out, a net change of +15 holders.
- The largest Cytek Biosciences buyer in Q4 2022 was Macquarie Group, an estimated $14.1M added.
- The largest Cytek Biosciences seller in Q4 2022 was Blue Water Life Science Advisors, an estimated $10.8M sold.
Based on aggregated 13F filings for Q4 2022.